Related Experiment Videos
How much do we gain by reducing time to reperfusion therapy?
1Duke Clinical Research Institute, Durham, North Carolina 27705, USA.
Insights
Rapid treatment for myocardial infarction (MI) significantly reduces adverse outcomes. While reducing patient presentation time is challenging, optimizing emergency department protocols can shorten treatment delays.
Area of Science:
- Cardiology
- Emergency Medicine
- Public Health
Background:
- Minimizing time from myocardial infarction (MI) symptom onset to thrombolytic therapy is crucial.
- Large trials show a direct correlation between faster treatment and reduced adverse clinical outcomes.
- The benefit of treatment within the first hour of MI symptom onset requires further investigation.
Purpose of the Study:
- To review factors influencing delays in MI treatment.
- To explore strategies for reducing pre-hospital and in-hospital delays.
- To assess the impact of emergency department interventions on treatment times.
Main Methods:
- Literature review of large-scale trials on MI treatment delays.
- Analysis of factors affecting patient presentation and treatment initiation.
- Evaluation of proposed interventions for streamlining emergency care.
Main Results:
- Patient characteristics influence presentation delays and mortality risk.
- Public education campaigns have had limited success in reducing presentation times.
- Treatment delays, though smaller than presentation delays, are reducible through field ECG transmission and streamlined ED protocols.
Conclusions:
- Reducing time-to-treatment for MI is essential for improving patient outcomes.
- While patient-side delays are difficult to shorten, optimizing emergency department workflows offers a promising avenue.
- Implementing strategies like field ECGs and rapid ED protocols can significantly decrease treatment delays.
Abstract:
Emphasis continues to be placed on the need to minimize the time elapsed between the onset of symptoms of myocardial infarction and the initiation of thrombolytic therapy. Numerous large-scale trials have revealed an inverse relation between time-to-treatment and the degree of reduction in the risk of adverse clinical outcomes. Still to be resolved is the question of whether additional benefit can be gained by treating within the first hour. Many factors that influence delays to presentation are also associated with a higher risk of mortality, and these factors vary with patient characteristics. These same factors are also associated with longer treatment delay and greater mortality risk. Although the greatest opportunity for reducing time-to-treatment lies in reducing presentation time, public education efforts have been largely unsuccessful. Despite the fact that treatment delay generally accounts for a smaller proportion of total delay time than does presentation delay, it may be more amenable to shortening through measures such as transmission of electrocardiograms from the field; emergency department protocols for the rapid triage, assessment, and treatment of patients with chest pain; training emergency department physicians to administer thrombolytic therapy without a cardiology consult; and storing thrombolytic agents in the emergency department.